Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations AdakveoⓇ - P-selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion ± Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients >=12 year old) 2024 (pediatric patients <12 year old) Abstract submission to ASH 2021 119 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation